Die Ophthalmologie最新文献

{"title":"[Systematic anamnesis for uveitis : Quick guide of the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA)].","authors":"","doi":"10.1007/s00347-025-02252-4","DOIUrl":"https://doi.org/10.1007/s00347-025-02252-4","url":null,"abstract":"","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144164145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Pseudoxanthoma elasticum-Novel therapeutic approaches on the horizon?]","authors":"Jonathan Meinke, Kristin Raming, Maximilian Pfau, Frank G Holz, Kristina Pfau","doi":"10.1007/s00347-025-02223-9","DOIUrl":"https://doi.org/10.1007/s00347-025-02223-9","url":null,"abstract":"<p><p>Pseudoxanthoma elasticum (PXE) is an inherited mineralization disorder that leads to calcification of elastic fibers. The ocular characteristics arise due to the calcification of Bruch's membrane, which is located between the retinal pigment epithelium and the choriocapillaris. Despite major scientific progress in understanding the underlying pathological mechanism in recent years, no causal treatment has so far been established. Therefore, the management of patients is currently limited to the treatment of secondary complications, such as intravitreal anti-vascular endothelial growth factor (VEGF) injections in cases of exudative neovascularization. This article discusses upcoming studies that aim to reduce ectopic mineralization. To confirm the diagnosis and possible inclusion in such studies a second assessment should therefore be carried out in a specialized center for PXE.</p>","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144164141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Letrozole-induced central serous chorioretinopathy].","authors":"Vesna Bosic, Berthold Seitz, Alaa Din Abdin","doi":"10.1007/s00347-025-02248-0","DOIUrl":"https://doi.org/10.1007/s00347-025-02248-0","url":null,"abstract":"","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144133127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Screening recommendations for glaucoma, age-related macular degeneration and diabetic eye diseases].","authors":"Lukas Schloesser, Focke Ziemssen, Alexander K Schuster, Somar Hasan, Robert P Finger","doi":"10.1007/s00347-025-02250-6","DOIUrl":"https://doi.org/10.1007/s00347-025-02250-6","url":null,"abstract":"<p><strong>Background: </strong>The main causes of blindness, age-related macular degeneration (AMD), glaucoma and diabetic eye diseases (DED), are becoming increasingly more important in terms of health economics due to the demographic developments.</p><p><strong>Objective: </strong>The current screening recommendations for these diseases and the underlying evidence are presented.</p><p><strong>Material and methods: </strong>A detailed literature search was conducted and the recommendations of the relevant guidelines of the Association of the Scientific Medical Societies in Germany (AWMF) were summarized.</p><p><strong>Results: </strong>There are current screening recommendations for glaucoma and DED but there is still no consensus with respect to AMD. Screening for DED is financed by the statutory health insurance (SHI) and offered as part of routine care. Glaucoma screening is only covered by the SHI if certain risk factors are present and is not yet implemented across the board.</p><p><strong>Conclusion: </strong>There are established screening programs for DED that are financed by the SHI; however, there are AWMF recommendations for glaucoma but no SHI-financed screening programs and there are still no AWMF screening recommendations for AMD. Whether and to what extent screening programs are used by the respective target populations should be further investigated in studies.</p>","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[My year with the DOG Leadership Academy].","authors":"Mariya Gosheva","doi":"10.1007/s00347-025-02260-4","DOIUrl":"https://doi.org/10.1007/s00347-025-02260-4","url":null,"abstract":"","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Faricimab in previously treated neovascular age-related macular degeneration : Study design of the prospective noninterventional study PASSENGER].","authors":"Britta Heimes-Bussmann, Rooschanak Bellenbaum, Christian Njoo, Sandra Liakopoulos, Steffen Schmitz-Valckenberg, Max Zortel, Kai Rothaus, Jost Leemhuis, Peter Mussinghoff, Albrecht Lommatzsch","doi":"10.1007/s00347-025-02258-y","DOIUrl":"https://doi.org/10.1007/s00347-025-02258-y","url":null,"abstract":"<p><strong>Background: </strong>Faricimab was approved in the European Union in 9/2022 as the first bispecific antibody for the treatment of neovascular age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DME) or retinal vein occlusion. To date, the efficacy profile of faricimab has been investigated under pivotal clinical phase 3 study conditions in treatment-naïve nAMD patients. The prospective noninterventional study (NIS) PASSENGER is a multicentre study that aims at contributing to a better understanding of the effectiveness, safety and impact of faricimab on quality of life in previously treated patients with nAMD under real-world conditions in Germany.</p><p><strong>Methods: </strong>The planned observation period per patient is 24 months. Patients (n = 620) aged ≥ 50 years with nAMD who switched to faricimab no longer than 12 weeks prior to enrolment in the study, were previously treated with a vascular endothelial growth factor (VEGF) inhibitor for a maximum of 36 months, and had a best corrected visual acuity (BCVA) of 30-80 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) scale at the start of therapy with faricimab are eligible to participate. The primary outcome measure is the change in BCVA from baseline after 52 weeks. In addition, central subfield thickness, intraretinal, subretinal and subpigment epithelial fluid over time as well as patient-reported outcomes, adherence and adverse events are recorded.</p><p><strong>Result: </strong>The first patient was enrolled in June 2023. According to the current schedule, recruitment (24 months) will be completed by June 2025 and the last patient visit is anticipated in Q2/2027.</p><p><strong>Conclusion: </strong>Data from the PASSENGER study are intended to contribute to a better understanding of therapy management in daily practice in Germany.</p>","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144112378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Awareness for age-related macular degeneration in the population-based AugUR study : Comparison of participant self-report with medical records data from treating ophthalmologists].","authors":"Martina E Zimmermann, Valentin Thanner, Horst Helbig, Klaus J Stark, Iris M Heid, Caroline Brandl","doi":"10.1007/s00347-025-02246-2","DOIUrl":"https://doi.org/10.1007/s00347-025-02246-2","url":null,"abstract":"<p><strong>Background: </strong>Limited awareness of existing age-related macular degeneration (AMD) can negatively affect the use of appropriate healthcare. This is particularly true for the older population, who are most commonly affected by AMD.</p><p><strong>Objectives: </strong>Analyzing the awareness of an existing AMD diagnosis in the older population. We evaluated AMD self-reports of participants of the population-based AugUR study aged ≥ 70 years in and around Regensburg using the records of treating ophthalmologists (BAA).</p><p><strong>Materials and methods: </strong>AMD self-reports of the AugUR participants were collected at study inclusion using interview-based questionnaires. An AMD diagnosis documented by the BAA was recorded by the BAA using an online questionnaire. Consensus or dissent of the available information was determined by creating a timeline for the date of study inclusion, the date of the first documented AMD diagnosis by the BAA and the date of the last visit to the BAA.</p><p><strong>Results: </strong>Self-report and BAA records on AMD were available for 1473 AugUR participants. Consensus was reached for 1270 individuals (86%). Of the 262 individuals with an existing BAA AMD diagnosis prior to study inclusion, 166 (63%) reported that they did not have AMD. In 137 of these 166 \"underreporters\", early stages of AMD were documented by the BAA.</p><p><strong>Conclusion: </strong>Our results suggest that 63% of the older population with a BAA-AMD diagnosis are unaware of their AMD diagnosis. Most of these diagnoses represent early stages of AMD, which may not be communicated to patients as \"AMD\". Improved awareness, including early forms of AMD, could support preventative behavior by those affected.</p>","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144082496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Bilateral choroidal neovascularization of rare origin : Secondary choroidal neovascularization in angioid streaks].","authors":"J F Eitle, S Kupferschmid","doi":"10.1007/s00347-025-02249-z","DOIUrl":"https://doi.org/10.1007/s00347-025-02249-z","url":null,"abstract":"","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144082498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Patient- and donor-dependent factors in descemet membrane endothelial keratoplasty and their impact on visual acuity and quality of life].","authors":"Thomas Hammer, P Wieland, J Horn, A Viestenz, A Viestenz","doi":"10.1007/s00347-025-02238-2","DOIUrl":"https://doi.org/10.1007/s00347-025-02238-2","url":null,"abstract":"<p><strong>Background: </strong>Descemet membrane endothelial keratoplasty (DMEK) is the gold standard for the treatment of endothelial corneal decompensation. The rapid postoperative improvement in visual acuity and the lower rejection rate of this minimally invasive procedure compared to penetrating keratoplasty justify the high acceptance of DMEK.</p><p><strong>Objective: </strong>The aim of this study was to analyse the general conditions for an optimal visual outcome after DMEK by recording patient- and graft-dependent factors.</p><p><strong>Study design and methods: </strong>A total of 72 eyes were retrospectively analysed in which Fuchs' endothelial dystrophy was treated by DMEK at the University Eye Hospital in Halle in 2019 and 2020. The data at the following timepoints were collected: preoperative graft examination, examination prior to surgery and one examination within the first 6 months postoperatively and one in the second postoperative year. In particular, the best corrected visual acuity (BCVA) and endothelial cell density were compared. A patient survey was used to evaluate the subjectively perceived success of the therapy. The main focus was on reduction in symptoms and the regained independence and participation in social life.</p><p><strong>Results: </strong>The BCVA increased from 0.37 ± 0.15 (logMAR 0.43 ± 0.82) preoperatively to 0.65 ± 0.18 (logMAR 0.19 ± 0.74) in the second postoperative year. The endothelial cell density of the transplant decreased from 2503 ± 206 cells/mm² preoperatively to 1441 ± 516 cells/mm² in the second postoperative year and thus decreased on average by 42%. The corneal thickness decreased from 599 ± 58 µm preoperatively to 521 ± 48 µm in the second postoperative year and decreased on average by 78 ± 71 µm. More than 70% of the patients surveyed complained of sensitivity to light (n = 66), blurred vision (n = 64) and reduced colour perception (n = 59). 57% (n = 50) reported symptoms of glare. 50% of patients (n = 50) felt that their vision was better at the time of the survey than preoperatively and 40% (n = 40) felt that it was optimal. Of those surveyed 84% (n = 84) described their quality of life postoperatively as better or even optimal.</p><p><strong>Conclusion: </strong>DMEK is an effective and safe procedure. The visual outcome can be influenced by various patient- and graft-dependent factors. Patients who had previously undergone other eye operations or had other eye diseases achieved a lower average postoperative increase in visual acuity. In addition, a correlation between donor gender and the decrease in endothelial cell density can be recognised. The endothelial cell loss in female donors is greater than in male donors.</p>","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144035981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Vitreous opacities in systemic amyloidosis].","authors":"Lukas Schloesser, Karin U Loeffler, Matthias M Mauschitz, Robert P Finger, Martina C Herwig-Carl","doi":"10.1007/s00347-025-02259-x","DOIUrl":"https://doi.org/10.1007/s00347-025-02259-x","url":null,"abstract":"","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}